Prior to joining Reshape LifesciencesR since February 2020, Mr. Hickey was the President and Chief Executive Officer of Altimate Medical Holdings, Inc. which designs and manufactures rehabilitation medical equipment including its EasyStand brand. Previously, from 2018 to 2020, he served as the President and Chief Executive Officer of Vertebral Technologies, Inc., a medical device company focused on implantable spinal devices. Prior to that, from 2016 to 2017, Mr. Hickey was Senior Vice President of Marketing and Reimbursement for EnteroMedics (now ReShape Lifesciences R). Earlier in his career, he consulted for a variety of commercialized medical device companies and held positions of increasing responsibility at Zimmer Biomet. For the past four years, Mr. Hickey has served on the Board of Directors at Excelen Center for Bone and Joint Research and Education.
Mr. Stankovich has over 25 years of executive leadership experience as the CFO for multiple public and private healthcare companies. Tom has spent the past nine years as the Global Senior Vice President and CFO of MP Biomedicals, a life sciences and molecular biology-diagnostics company. At MP Biomedicals he was responsible for financial planning and reporting, financial operations and strategy development along with the acquisition and integration of two international companies. Prior to MP Biomedicals, Tom served as CFO at Response Genetics where he successfully led the company through their initial public offering. Additionally, he served as CFO for Cobalis Corporation and for Ribapharm, where he also led the company through their initial public offering, which at the time became the second largest ever IPO in the biotechnology sector. Tom also held CFO positions at ICN International, which later changed names to Valeant Pharmaceuticals.
Prior to joining Reshape Lifesciences, since November 2020, Mr. Ansari was the Chief Commercial Officer and General Manager of Biedermann-Motech Inc., a mid-sized, international, family owned, and operated group of companies focused on the development, production and distribution of innovative implants and instruments for spinal and extremity surgery. From August 2019 until November 2020, he was Executive Vice President – Sales & Marketing at Biocell Spine Consulting, Inc. where he was responsible for commercializing the company’s innovative neuromodulation device for peripheral pain. Before that, from January 2015 until July 2019, he was Senior Vice President Global Sales at Enteromedics, during which time he led a 700% increase in device sales and was a key member of the executive due diligence team responsible for purchasing the Lap-Band® business. Before that, from January 2013 to January 2015, he was President/Exclusive Biomet-Lanx Distributor at Biocell Spine, LLC, and for three years prior to that, served in positions of increasing responsibility at Lanx, Inc., a spine orthopedic medical device manufacturer, subsequently acquired by Zimmer Biomet. Earlier in his career, Mr. Ansari honed his sales and distributorship skills at companies including Globus Medical, Inc., Biomet Orthopaedics Inc. (now Zimmer Biomet), Medtronic Sofamor-Danek, Johnson & Johnson DePuy Ortho Tech (now DePuy Synthes) and Stryker Corporation. Mr. Ansari holds a Bachelor of Arts degree from Winthrop University.
Mr. Diaz joined the company as Vice President of Operations in August of 2021. Mr. Diaz possesses over thirty years of executive leadership experience in operations and engineering in implantable and non-implantable devices. Most recently, he served as Executive Vice President of Operations at ClearFlow, Inc. Mr. Diaz also held executive operational positions at the following companies: VasoNova, Inc. (Teleflex), Cardio Output Technologies, Inc., United States Manufacturing Company, Biolase Technology, Inc., Sorin Biomedica, Italy, Laerdal Medical, and Advanced Interventional Systems. Additionally, from 2003 until 2016, he was the Owner and President of Azmec, Inc., a manufacturer, and distributor of orthopedic soft goods.
Dr. Gal joined the Company as Vice President, Regulatory Clinical Quality & Compliance Officer in September 2019. With more than 30-year experience as a practicing veterinarian, academician at Tufts University School of Medicine and subsequently in the medtech industry. Prior to joining ReShape Lifesciences, Dr. Gal held R&D, clinical marketing and clinical affairs positions in private start-up, and medium to large public medical device companies. Specifically, Dr. Gal led the regulatory, clinical and quality departments at ClearFlow Inc., the clinical department of the Heart Valve Therapy business at Edwards Lifesciences, the clinical department at Broncus Technologies, and was the director of clinical research at Medtronic Vascular. Dr. Gal holds a BSc. degree in biology from Tel Aviv University, Tel Aviv Israel, Doctor of Veterinary Medicine degree from Pisa University, Pisa Italy, and an MBA degree from Boston University, Boston, Massachusetts.